|

Ketorolac in Upper Extremity Tendinopathy and Arthropathy

RECRUITINGPhase 4Sponsored by Emory University
Actively Recruiting
PhasePhase 4
SponsorEmory University
Started2023-01-31
Est. completion2027-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations4 sites

Summary

Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints. The goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy. Participants will be blinded to the treatment received. The duration of an individual participant's participation in this study is 24 weeks. During this time period, patients will be asked to return to the clinic for an in-person follow-up 6 weeks after the injection with either ketorolac or triamcinolone) in order to assess participants' outcomes. All work related to this project will take place at the Emory Sports Medicine Complex, Emory Executive Park, Emory Musculoskeletal Institute, the Emory University Orthopaedic and Spine Hospital, and the Emory Saint Joseph's Hospital. This study will add to existing knowledge by providing further insight into how wrist arthropathy should be most optimally and conservatively managed.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 or older,
* symptomatic tendinopathy or arthropathy of the shoulder, elbow, hand, or wrist who have not undergone prior surgical treatment for their condition.
* Diagnoses may include trigger finger, De Quervain's tenosynovitis, radiocarpal osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, or proximal interphalangeal joint osteoarthritis.

Exclusion Criteria:

* Patients under the age of 18,
* Patients who have undergone prior triamcinolone or ketorolac injections within the past 6 months,
* Patients who have undergone prior surgical treatment for their hand condition,
* Patients with allergy or contraindication to triamcinolone or ketorolac injection,
* Patients with an active infection at the treatment site \[active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. white blood cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)\].

Conditions4

ArthritisArthropathyOsteoarthritisTendinopathy

Locations4 sites

Emory Saint Joseph's Hospital
Atlanta, Georgia, 30308
Paul A. Ghareeb, MD(404) 778-3350paul.ghareeb@emory.edu
Emory University Orthopaedic and Spine Center
Atlanta, Georgia, 30324
Amanda L Demsey, MD(404) 778-6381amanda.l.dempsey@emory.edu
12 Executive Park Drive
Atlanta, Georgia, 30329
Paul A. Ghareeb, MD(404) 778-3350paul.ghareeb@emory.edu
Emory University Orthopaedic and Spine Hospital
Atlanta, Georgia, 30329
Paul A. Ghareeb, MD404-778-3350paul.ghareeb@emory.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.